Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...
Збережено в:
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Англійська |
| Опубліковано: |
2019
|
| Онлайн доступ: | https://doi.org/10.1038/s41375-019-0384-1 https://www.nature.com/articles/s41375-019-0384-1.pdf |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|